J Thromb Haemost:依诺肝素预防妊娠相关静脉血栓栓塞的有效性和安全性

2019-04-24 xing.T 网络

由此可见,在该队列中使用标准剂量依诺肝素进行血栓预防可有效预防PA-VTE。在分娩和分娩期间经常使用椎管内镇痛/麻醉,并且使用较高剂量的依诺肝素可能阻碍了该途径。产后出血很常见,较高剂量的血栓预防可能会增加产科出血并发症。这些数据并未表明在临床环境中需要考虑更高剂量的依诺肝素用于血栓预防。

低分子量肝素(LMWH)用于预防妊娠相关的静脉血栓栓塞(PA-VTE),但数据有限,无法确定哪些女性需要在妊娠期间进行血栓预防,并哪种LMWH剂量有效和安全仍具争议。近日,血栓和凝血疾病权威杂志Journal of Thrombosis and Haemostasis上发表了一篇研究文章,研究人员旨在评估1999年至2014年期间在新西兰奥克兰的国家妇女医院(一家三级产科转诊中心)接受治疗的PA-VTE风险女性使用依诺肝素进行血栓预防的效率和并发症的发生率。

这是一项回顾性观察性研究,对产妇使用依诺肝素进行血栓预防,以便在产科或产妇胎儿医疗团队的护理下预防PA-VTE。 

研究人员确定了123名妇女的172次妊娠。在94.8%的妊娠中使用了单日剂量40mg的依诺肝素,发生了2例PA-VTE[1.2%(95%CI为0.32-4.14)]。产后出血(PPH)>500ml的发生率为36.6%,PPH>1000ml的发生率为9.3%。只有四名妇女接受输血。神经镇痛/麻醉用于52.4%的分娩,包括39.6%的阴道分娩。 

由此可见,在该队列中使用标准剂量依诺肝素进行血栓预防可有效预防PA-VTE。在分娩和分娩期间经常使用椎管内镇痛/麻醉,并且使用较高剂量的依诺肝素可能阻碍了该途径。产后出血很常见,较高剂量的血栓预防可能会增加产科出血并发症。这些数据并未表明在临床环境中需要考虑更高剂量的依诺肝素用于血栓预防。 

原始出处:

Stephanie Cox.et al.Effectiveness and Safety of Thromboprophylaxis with Enoxaparin for Prevention of Pregnancy‐Associated Venous Thromboembolism.Journal of Thrombosis and Haemostasis.2019.https://doi.org/10.1111/jth.14452

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1072059, encodeId=033510e2059e8, content=已阅,受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Sat Nov 20 10:15:05 CST 2021, time=2021-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955430, encodeId=5bc219554307a, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Fri Jun 07 15:44:00 CST 2019, time=2019-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008421, encodeId=9e472008421c9, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Wed Mar 04 15:44:00 CST 2020, time=2020-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697892, encodeId=1033169e8924e, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Sun Oct 27 07:44:00 CST 2019, time=2019-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366863, encodeId=c5443668635f, content=努力学习天天学习天天学习天天学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQpl0ENSJScphsFtdgfibXX1g1IuEYGCjP23UqCd52TxTpSZibtPiclyusaHicnNXd78alaia19Qy1nAFo18/0, createdBy=50381491660, createdName=zwjnj2, createdTime=Mon May 27 12:22:12 CST 2019, time=2019-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378987, encodeId=135313e89870d, content=<a href='/topic/show?id=b0392692831' target=_blank style='color:#2F92EE;'>#依诺肝素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26928, encryptionId=b0392692831, topicName=依诺肝素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Fri Apr 26 03:44:00 CST 2019, time=2019-04-26, status=1, ipAttribution=)]
    2021-11-20 湘雅科教

    已阅,受益匪浅。

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1072059, encodeId=033510e2059e8, content=已阅,受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Sat Nov 20 10:15:05 CST 2021, time=2021-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955430, encodeId=5bc219554307a, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Fri Jun 07 15:44:00 CST 2019, time=2019-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008421, encodeId=9e472008421c9, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Wed Mar 04 15:44:00 CST 2020, time=2020-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697892, encodeId=1033169e8924e, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Sun Oct 27 07:44:00 CST 2019, time=2019-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366863, encodeId=c5443668635f, content=努力学习天天学习天天学习天天学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQpl0ENSJScphsFtdgfibXX1g1IuEYGCjP23UqCd52TxTpSZibtPiclyusaHicnNXd78alaia19Qy1nAFo18/0, createdBy=50381491660, createdName=zwjnj2, createdTime=Mon May 27 12:22:12 CST 2019, time=2019-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378987, encodeId=135313e89870d, content=<a href='/topic/show?id=b0392692831' target=_blank style='color:#2F92EE;'>#依诺肝素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26928, encryptionId=b0392692831, topicName=依诺肝素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Fri Apr 26 03:44:00 CST 2019, time=2019-04-26, status=1, ipAttribution=)]
    2019-06-07 xue8602
  3. [GetPortalCommentsPageByObjectIdResponse(id=1072059, encodeId=033510e2059e8, content=已阅,受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Sat Nov 20 10:15:05 CST 2021, time=2021-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955430, encodeId=5bc219554307a, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Fri Jun 07 15:44:00 CST 2019, time=2019-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008421, encodeId=9e472008421c9, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Wed Mar 04 15:44:00 CST 2020, time=2020-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697892, encodeId=1033169e8924e, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Sun Oct 27 07:44:00 CST 2019, time=2019-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366863, encodeId=c5443668635f, content=努力学习天天学习天天学习天天学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQpl0ENSJScphsFtdgfibXX1g1IuEYGCjP23UqCd52TxTpSZibtPiclyusaHicnNXd78alaia19Qy1nAFo18/0, createdBy=50381491660, createdName=zwjnj2, createdTime=Mon May 27 12:22:12 CST 2019, time=2019-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378987, encodeId=135313e89870d, content=<a href='/topic/show?id=b0392692831' target=_blank style='color:#2F92EE;'>#依诺肝素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26928, encryptionId=b0392692831, topicName=依诺肝素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Fri Apr 26 03:44:00 CST 2019, time=2019-04-26, status=1, ipAttribution=)]
    2020-03-04 changfy
  4. [GetPortalCommentsPageByObjectIdResponse(id=1072059, encodeId=033510e2059e8, content=已阅,受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Sat Nov 20 10:15:05 CST 2021, time=2021-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955430, encodeId=5bc219554307a, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Fri Jun 07 15:44:00 CST 2019, time=2019-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008421, encodeId=9e472008421c9, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Wed Mar 04 15:44:00 CST 2020, time=2020-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697892, encodeId=1033169e8924e, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Sun Oct 27 07:44:00 CST 2019, time=2019-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366863, encodeId=c5443668635f, content=努力学习天天学习天天学习天天学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQpl0ENSJScphsFtdgfibXX1g1IuEYGCjP23UqCd52TxTpSZibtPiclyusaHicnNXd78alaia19Qy1nAFo18/0, createdBy=50381491660, createdName=zwjnj2, createdTime=Mon May 27 12:22:12 CST 2019, time=2019-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378987, encodeId=135313e89870d, content=<a href='/topic/show?id=b0392692831' target=_blank style='color:#2F92EE;'>#依诺肝素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26928, encryptionId=b0392692831, topicName=依诺肝素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Fri Apr 26 03:44:00 CST 2019, time=2019-04-26, status=1, ipAttribution=)]
    2019-10-27 fusion
  5. [GetPortalCommentsPageByObjectIdResponse(id=1072059, encodeId=033510e2059e8, content=已阅,受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Sat Nov 20 10:15:05 CST 2021, time=2021-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955430, encodeId=5bc219554307a, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Fri Jun 07 15:44:00 CST 2019, time=2019-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008421, encodeId=9e472008421c9, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Wed Mar 04 15:44:00 CST 2020, time=2020-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697892, encodeId=1033169e8924e, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Sun Oct 27 07:44:00 CST 2019, time=2019-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366863, encodeId=c5443668635f, content=努力学习天天学习天天学习天天学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQpl0ENSJScphsFtdgfibXX1g1IuEYGCjP23UqCd52TxTpSZibtPiclyusaHicnNXd78alaia19Qy1nAFo18/0, createdBy=50381491660, createdName=zwjnj2, createdTime=Mon May 27 12:22:12 CST 2019, time=2019-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378987, encodeId=135313e89870d, content=<a href='/topic/show?id=b0392692831' target=_blank style='color:#2F92EE;'>#依诺肝素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26928, encryptionId=b0392692831, topicName=依诺肝素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Fri Apr 26 03:44:00 CST 2019, time=2019-04-26, status=1, ipAttribution=)]
    2019-05-27 zwjnj2

    努力学习天天学习天天学习天天学习

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1072059, encodeId=033510e2059e8, content=已阅,受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Sat Nov 20 10:15:05 CST 2021, time=2021-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955430, encodeId=5bc219554307a, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Fri Jun 07 15:44:00 CST 2019, time=2019-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008421, encodeId=9e472008421c9, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Wed Mar 04 15:44:00 CST 2020, time=2020-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697892, encodeId=1033169e8924e, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Sun Oct 27 07:44:00 CST 2019, time=2019-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366863, encodeId=c5443668635f, content=努力学习天天学习天天学习天天学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQpl0ENSJScphsFtdgfibXX1g1IuEYGCjP23UqCd52TxTpSZibtPiclyusaHicnNXd78alaia19Qy1nAFo18/0, createdBy=50381491660, createdName=zwjnj2, createdTime=Mon May 27 12:22:12 CST 2019, time=2019-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378987, encodeId=135313e89870d, content=<a href='/topic/show?id=b0392692831' target=_blank style='color:#2F92EE;'>#依诺肝素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26928, encryptionId=b0392692831, topicName=依诺肝素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Fri Apr 26 03:44:00 CST 2019, time=2019-04-26, status=1, ipAttribution=)]

相关资讯

Chest:依诺肝素和达肝素在创伤后血栓预防中的疗效比较!

由此可见,达肝素对创伤患者中也有与依诺肝素一样的效果。未来的研究应该进一步探究预防的时间和一致性对LMWH有效性的影响。

Ann Pharmacother:儿科患者应如何选择依诺肝素的剂量?

2018年2月,发表在《Ann Pharmacother》的一项由美国科学家进行的研究考察了依诺肝素在儿科患者中的群体药物代谢动力学。

JAMA Surg:依诺肝素预防静脉血栓栓塞

背景:对于外科手术和创伤患者可使用预防剂量依诺肝素预防静脉血栓栓塞(VTE);尽管如此,VTE发病率和死亡率仍很高,并且抗凝血酶Ⅲ或抗Xa因子不足、以及错误的依诺肝素剂量等均会加剧VTE风险。最近的数据表明,标准肝素酶和血栓弹力图(TEG)之间的反应时间(初始纤维蛋白形成时间)差异大于1分钟与VTE风险的降低有关。目的:评估TEG调整的预防剂量依诺肝素对外伤及手术患者VTE风险预防的有效性。方法:

Am J Obstet Gynecol:依诺肝素能否降低先兆子痫和低于胎龄妊娠史女性复发风险?

先兆子痫和低于胎龄妊娠是产妇和围产期发病率和死亡率的主要原因。具有既往被这些疾病影响的妊娠史的女性在将来妊娠中复发的风险增加。过去进行了评估低分子量肝素预防先兆子痫和低于胎龄妊娠有效性的试验,但是试验给出了矛盾的结果,并且当各试验相互比较时,异质性水平很高。2017年3月,发表在《Am J Obstet Gynecol.》的一项开放标签的随机对照试验对此进行调查。目的:研究人员旨在评估具有先兆子痫

Obstet Gynecol:依诺肝素联合阿司匹林和单纯阿司匹林在治疗胎盘介导的妊娠并发症中哪个更强?

产前预防性使用依诺肝素并不能显著降低采用低剂量肝素治疗在妊娠34周以前诊断重度先兆子痫孕妇由胎盘介导的妊娠并发症。

Chest:创伤患者血栓预防:达肝素vs依诺肝素

有效的血栓预防对创伤人群必不可少。静脉血栓栓塞(VTE)是创伤患者中第三常见的并发症。依诺肝素和达肝素是最广泛使用的两种低分子肝素(LMWH)药物。虽然LMWH被认为是创伤患者使用的黄金标准,但只证明了依诺肝素的有效性。2017年8月,发表在《Chest》的一项由美国科学家进行的研究,比较了依诺肝素和达肝素在创伤后血栓预防中的疗效。